Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongxia Wei

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Allergy|March 29, 2025
Clinical, Epidemiological, Virological Characteristics and Outcomes of 286 Patients Infected With Monkeypox Virus in ChinaHankun Hu, Yang Zheng, Lianguo Ruan, et al.
Frontiers in Pharmacology|January 11, 2020
Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in ChinaXiaojie Huang, Liumei Xu, Lijun Sun, et al.
Journal of Thoracic Disease|December 7, 2020
Comparison of clinical characteristics between patients with coronavirus disease 2019 (COVID-19) who retested RT-PCR positive versus negative: a retrospective study of data from NanjingYuan Liu, Ning Ding, Shixiang Zhou, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
(5R)-5-hydroxytriptolide for HIV immunological non-responders receiving ART: a randomized, double-blinded, placebo-controlled phase II studyWei Cao, Xiaosheng Liu, Yang Han, et al.
Infectious Diseases of Poverty|August 14, 2023
Immediate and long-term outcomes after treat-all among people living with HIV in China: an interrupted time series analysisXinsheng Wu, Guohui Wu, Ping Ma, et al.
The Lancet Regional Health. Western Pacific|August 7, 2023
Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96Bin Su, Guiju Gao, Min Wang, et al.
Scientific Reports|June 18, 2017
Burden of sleep disturbances and associated risk factors: A cross-sectional survey among HIV-infected persons on antiretroviral therapy across ChinaXiaojie Huang, Huiqin Li, Kathrine Meyers, et al.
Nature Communications|August 13, 2024
Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alterationLinjing Zhu, Bilian Huang, Xiangyao Wang, et al.
The Lancet Regional Health. Western Pacific|August 15, 2022
The impact of COVID-19 non-pharmaceutical interventions on HIV care continuum in China: An interrupted time series analysisXinsheng Wu, Guohui Wu, Yanmin Ma, et al.
Science Translational Medicine|November 19, 2025
A rationally designed cocktail of nanobodies elicited by heterologous vaccination confers protection against SFTSV in preclinical modelsXilin Wu, Linjing Zhu, Shengjian Liang, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Allergy|March 29, 2025
Clinical, Epidemiological, Virological Characteristics and Outcomes of 286 Patients Infected With Monkeypox Virus in ChinaHankun Hu, Yang Zheng, Lianguo Ruan, et al.
Frontiers in Pharmacology|January 11, 2020
Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in ChinaXiaojie Huang, Liumei Xu, Lijun Sun, et al.
Journal of Thoracic Disease|December 7, 2020
Comparison of clinical characteristics between patients with coronavirus disease 2019 (COVID-19) who retested RT-PCR positive versus negative: a retrospective study of data from NanjingYuan Liu, Ning Ding, Shixiang Zhou, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
(5R)-5-hydroxytriptolide for HIV immunological non-responders receiving ART: a randomized, double-blinded, placebo-controlled phase II studyWei Cao, Xiaosheng Liu, Yang Han, et al.
Infectious Diseases of Poverty|August 14, 2023
Immediate and long-term outcomes after treat-all among people living with HIV in China: an interrupted time series analysisXinsheng Wu, Guohui Wu, Ping Ma, et al.
The Lancet Regional Health. Western Pacific|August 7, 2023
Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96Bin Su, Guiju Gao, Min Wang, et al.
Scientific Reports|June 18, 2017
Burden of sleep disturbances and associated risk factors: A cross-sectional survey among HIV-infected persons on antiretroviral therapy across ChinaXiaojie Huang, Huiqin Li, Kathrine Meyers, et al.
Nature Communications|August 13, 2024
Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alterationLinjing Zhu, Bilian Huang, Xiangyao Wang, et al.
The Lancet Regional Health. Western Pacific|August 15, 2022
The impact of COVID-19 non-pharmaceutical interventions on HIV care continuum in China: An interrupted time series analysisXinsheng Wu, Guohui Wu, Yanmin Ma, et al.
Science Translational Medicine|November 19, 2025
A rationally designed cocktail of nanobodies elicited by heterologous vaccination confers protection against SFTSV in preclinical modelsXilin Wu, Linjing Zhu, Shengjian Liang, et al.
Pageof 11